HOXD13 and urinary bladder carcinoma: To explore whether there was an association between plasma sPD-1 concentration and clinical responses in patients with cancer receiving PD-1 blockade therapy, we measured sPD-1 concentrations in plasma collected from 22 patients (12 with NSCLC, 9 with gastric cancer, and 1 with bladder cancer) at diagnosis and after two and four cycles of anti-PD-1 antibody therapy.